Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Samsung, Qualcomm 2nm Chip Deal Delayed Over Pricing 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build 
Japanese Yen Nears Seven-Month High as Oil Approaches $100 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Brent Oil Tops $100 as Middle East Conflict Threatens Supply 
Apple Unveils $1,999 Foldable iPhone Duo 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Anthropic Drops $6 Billion Decart AI Acquisition Talks 
Add as a preferred source on Google
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
